Literature DB >> 6482320

[Anti-HBc IgM in acute and chronic hepatitis B virus infection].

K Gmelin, L Theilmann, G Hasche, H Will, P Czygan, H W Doerr, B Kommerell.   

Abstract

Hepatitis B core antigen (HBcAg) synthesized in E. coli was used for determination of immunoglobulin M class-specific antibodies against HBcAg. It was found that 98% of cases with acute hepatitis B surface antigen (HBsAg) positive hepatitis type B were anti-HBc immunoglobulin M (IgM) positive. Atypical hepatitis B was detected in 33% of anti-HBc-positive HBsAg-negative cases with acute hepatitis. Anti-HBc IgM was positive for 6 months in acute resolving hepatitis type B, whereas cases resulting in chronic hepatitis B remained anti-HBc IgM-positive for up to 900 days. Chronic HBsAg carriers with severe liver disease had anti-HBc IgM more often than individuals with minor liver damage; 83% of HBsAg-positive liver cirrhoses, 63% of chronic aggressive hepatitis, 50% of HBsAg-positive liver carcinoma, but only 17% of chronic persistent hepatitis or 7% of healthy blood donors were anti-HBc IgM-positive. Determination of anti-HBc IgM is useful in detecting atypical hepatitis B virus infections without HBsAg in serum and, with some restrictions, in discriminating acute and chronic hepatitis type B.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6482320     DOI: 10.1007/bf01711864

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  31 in total

1.  Hepatocellular cancer in Southern African blacks: HBeAg, anti-HBe, IgM-anti-HBc and other markers of hepatitis B.

Authors:  M C Kew; J Desmyter; G De Groote; G Frösner; M Roggendorf; F Deinhardt
Journal:  Prog Med Virol       Date:  1981

2.  Dane particle DNA polymerase and HBeAg: impact on clinical, laboratory, and histologic findings in hepatitis B-associated chronic liver disease.

Authors:  L L Andres; V K Sawhney; G H Scullard; J L Smith; T C Merigan; W S Robinson; P B Gregory
Journal:  Hepatology       Date:  1981 Nov-Dec       Impact factor: 17.425

3.  IgM-anti-HBc as a marker of persistent and IgG-anti-HBc as a marker of past hepatitis B infection. A longitudinal study over 5 years.

Authors:  P Niermeiier; C H Gips; J R Huizenga; J Ringers; S Verkerk; H J Houthuff; B Houwen; J A Snijder; J O Nielsen
Journal:  Acta Hepatogastroenterol (Stuttg)       Date:  1978-10

4.  Hepatitis B virus core antigen: synthesis in Escherichia coli and application in diagnosis.

Authors:  S Stahl; P MacKay; M Magazin; S A Bruce; K Murray
Journal:  Proc Natl Acad Sci U S A       Date:  1982-03       Impact factor: 11.205

5.  Enzyme-linked immunosorbent assay for detection of immunoglobulin M antibody to hepatitis B core antigen.

Authors:  P Kryger; L R Mathiesen; A M Møller; J Aldershvile; B G Hansson; J O Nielsen
Journal:  J Clin Microbiol       Date:  1981-03       Impact factor: 5.948

6.  Immunoglobulin M antibodies to hepatitis B core antigen: evaluation of enzyme immunoassay for diagnosis of hepatitis B virus infection.

Authors:  M Roggendorf; F Deinhardt; G G Frösner; R Scheid; B Bayerl; R Zachoval
Journal:  J Clin Microbiol       Date:  1981-04       Impact factor: 5.948

7.  The IgM antibody responses to the core antigen of hepatitis B virus.

Authors:  B J Cohen
Journal:  J Med Virol       Date:  1978       Impact factor: 2.327

8.  Comparison of hepatitis B core antigens derived from human liver or synthesized in Escherichia coli and evaluation of their use in diagnostic assays for anti-HBc IgM.

Authors:  M Roggendorf; F Deinhardt; R Zachoval; K von der Helm
Journal:  J Virol Methods       Date:  1983-02       Impact factor: 2.014

9.  The binding constants of IgM rheumatoid factors and their univalent fragments for native and aggregated human IgG;.

Authors:  S Dissanayake; F C Hay; I M Roitt
Journal:  Immunology       Date:  1977-03       Impact factor: 7.397

10.  Comparison of different methods for the detection of rubella-specific IgM antibodies.

Authors:  R Braun; H W Doerr; H P Geisen; C Hornig; U Huschka; K Munk
Journal:  J Med Virol       Date:  1981       Impact factor: 2.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.